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Our paper reported small peptide inhibitors of the Plk1 polo-box domain (PBD) that were designed to contain monoanionic phospho-
threonine esters. Subsequent analysis has revealed that the structures of peptides 2b–2n, 2c*, 2m*, and 3; their associated serine to
alanine (S/A) variants; and the X-ray cocrystal structure of 2m bound to the Plk1 PBD (PDB accession code 4MLU) are not as pre-
sented in the paper. The pThr residues, whichwere reported as beingmonoanionic or neutral, are instead dianionic andmonoanionic,
respectively. Therefore, the interpretation of the data as reflecting the ability of peptides containing amonoanionic phosphothreonine
residue to exhibit high PBD-binding affinity and enhanced cellular efficacy as well as the role of pivaloyloxymethyl (POM) prodrug
protection in the observed biological effects are not valid in light of the incorrect structural assignments. As a result, the authors
retract the paper.1254 Chemistry & Biology 21, 1254, September 18, 2014 ª2014 Elsevier Ltd All rights reserved
